ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Health Technology

Sun Pharmaceutical Industries Ltd.

  • 426.15 INR
  • +4.60
  • +1.09%
  • India
    Jul 19, 2019
  • Ticker
  • Prev. close
  • Market cap (INR)
  • Market cap (USD)
  • Shares

Business Summary

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It operates through the following geographical segments: India, United States of America, Emerging Markets, and Rest of the World. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1982 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2019 INRUSD
Gross Profit134,766M1,926.80M
Operating income45,543.40M651.15M
Income before tax38,102M544.76M
Net income26,654.20M381.08M
Diluted EPS11.110.15
Dividends Per Share----
Total Assets646,938.10M9,338.69M
Total liabilities199,712.10M2,882.88M
Total equity414,090.60M5,977.48M
Operating cash flow----
Currency in INRCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 272,865M 281,086.10M 313,081.40M 264,155.40M 290,659.10M
Gross Profit 140,261.50M 149,951.40M 158,651.20M 109,049.50M 134,766M
Operating income 68,831.20M 75,140.60M 84,884.50M 40,954.10M 45,543.40M
Income before tax 64,029M 65,706.30M 90,478.70M 34,789.80M 38,102M
Net income 45,393.80M 45,457.10M 69,643.70M 21,615.50M 26,654.20M
EBITDA 80,778.40M 85,515.90M 97,532M 55,952.50M 63,075.90M
Diluted EPS 18.90 18.90 29 9 11.11
Dividends Per Share 3 1 3.50 2 --
Total Assets 494,235.80M 559,415.90M 619,117.90M 649,909.70M 646,938.10M
Total liabilities 209,343M 188,572.10M 214,674.70M 230,062.50M 199,712.10M
Total equity 256,231.90M 329,824.80M 366,396.70M 381,005.60M 414,090.60M
Operating cash flow 53,591.20M 67,726.30M 71,269.50M 39,781.60M --
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 4,462.70M 4,293.30M 4,668.88M 4,097.58M 4,155.67M
Gross Profit 2,293.97M 2,290.35M 2,365.91M 1,691.58M 1,926.80M
Operating income 1,125.73M 1,147.69M 1,265.85M 635.28M 651.15M
Income before tax 1,047.19M 1,003.59M 1,349.27M 539.66M 544.76M
Net income 742.41M 694.31M 1,038.57M 335.30M 381.08M
EBITDA 1,321.12M 1,306.16M 1,454.46M 867.93M 901.82M
Diluted EPS 0.30 0.28 0.43 0.13 0.15
Dividends Per Share 0.04 0.01 0.05 0.03 --
Total Assets 7,897.50M 8,447.51M 9,534.42M 9,964.62M 9,338.69M
Total liabilities 3,345.13M 2,847.55M 3,305.99M 3,527.39M 2,882.88M
Total equity 4,094.38M 4,980.55M 5,642.51M 5,841.70M 5,977.48M
Operating cash flow 876.48M 1,034.44M 1,062.81M 617.09M --

Valuation Measures

Mar 2019
Operating margin15.66%
Profit margin9.17%

Key executives

  • Managing Director & Executive Director: Dilip Shantilal Shanghvi
  • Chief Financial Officer: C. S. Muralidharan
  • Compliance Officer & Senior GM-Secretarial: Ashok I. Bhuta
  • Vice President & Global Head-Regulatory: Rajeev S. Mathur
  • Senior Vice President-Business Development: Kirti Wardhaman Ganorkar


  • Life Insurance Corp. of India (5.8%)
  • ICICI Prudential Asset Management Co. Ltd. (3.6%)
  • Aditya Medisales Ltd. (1.6%)
  • The Vanguard Group, Inc. (1.5%)
  • Reliance Nippon Life Asset Management Ltd. (Invt Mgmt) (1.4%)
  • GIC Pte Ltd. (Investment Management) (1.3%)
  • Lakshdeep Investments & Finance Pvt Ltd. (1.3%)

Contact Details

  • Website:
  • Address: CTS No. 201 B/1, Sun House, Western Express Highway, Mumbai, 400063, India
  • Phone: +91.22.43244324

Related Companies

  • Sun Pharmaceuticals Germany GmbH
  • Sun Pharmaceuticals Morocco LLC Sarlau
  • Sun Pharma Netherlands BV
  • Sun Pharmaceutical Industries (Australia) Pty Ltd.
  • Ocular Technologies SARL
  • Sun Pharmaceutical Industries Ltd. /7 Brands/
  • Sun Pharmaceutical Industries Ltd. /Bryan Ops/
  • GlaxoSmithKline Plc /Opiates Business/
  • Sun Pharma Laboratories Ltd.
  • Sun Global Canada Pty Ltd.
  • Sun Pharmaceutical Industries Europe BV
  • Aditya Acquisition Co. Ltd.
  • SPIL de Mexico SA de CV
  • Sun Pharma de Mexico SA de CV
  • Tamil Nadu Dadha Pharmaceuticals Ltd.
  • Pradeep Drug Co. Ltd.
  • Pola Pharma, Inc.
  • Ranbaxy
  • Pharmalucence, Inc.
  • Alkaloida Chemical Co. Exclusive Group Ltd.
  • Sun Pharmaceutical Industries Key Employees Benefit Trust
  • Sun Pharmaceutical Industries, Inc.
  • Chattem Chemicals, Inc.
  • Generic Pharmaceutical Co.
  • Zenotech Laboratories Limited
  • MJ Pharmaceuticals Ltd. /Manufacturing Business/
  • MJ Pharmaceuticals Pvt Ltd.
  • Phlox Pharmaceuticals Ltd.
  • Hindustan Antibiotics Ltd.
  • Gujarat Lyka Organics Ltd


  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Glenmark Pharmaceuticals Limited
  • IPCA Laboratories Limited
  • Wockhardt Limited
  • FDC Ltd.
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd
  • Cadila Healthcare Limited
  • Amneal Pharmaceuticals, Inc. Class A
  • ANI Pharmaceuticals, Inc.
  • Zentiva SA
  • Cytori Therapeutics, Inc.
  • Antares Pharma, Inc.
  • Aerie Pharmaceuticals, Inc.
  • Nicox SA
  • Cumberland Pharmaceuticals Inc.
  • Chunghwa Chemical Synthesis & Biotech Co., Ltd. Class A
  • Curis, Inc.
  • Acura Pharmaceuticals, Inc.
  • BioPharmX Corp.
  • Evolus, Inc.
  • Intec Pharma Ltd
  • Sol-Gel Technologies Ltd.
Last Updated on 19 Jul, 2019

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends June 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media